Online inquiry

IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3661MR)

This product GTTS-WQ3661MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets F11 gene. The antibody can be applied in Thromobosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000128.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2160
UniProt ID P03951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3661MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10758MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ13693MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ5097MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CAM-3001
GTTS-WQ15055MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SRF-231
GTTS-WQ3039MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ3238MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ARGX-113
GTTS-WQ3792MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ14124MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aPCSK927
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW